PMID- 36045524
OWN - NLM
STAT- MEDLINE
DCOM- 20230519
LR  - 20230519
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 30
IP  - 25
DP  - 2023
TI  - Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
PG  - 2850-2863
LID - 10.2174/0929867329666220831151645 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and 
      morbidity worldwide. It leads to various long-term complications such as diabetic 
      nephropathy. Diabetes nephropathy is the leading cause of renal failure in 
      patients with chronic kidney diseases undergoing hemodialysis. Hence preventing 
      the development and progression of diabetic nephropathy is one of the main goals 
      in the management of patients with type 2 diabetes. Sodium-glucose cotransporter 
      2 inhibitors of empagliflozin is a potent anti-hyperglycemic agents. In addition, 
      it has been shown to have some pharmacologic potentials to provide renoprotective 
      effects in patients with T2DM. In the current study, we review the available 
      clinical data on the potential renoprotective effects of this drug from a 
      mechanistic and molecular viewpoint.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Yaribeygi, Habib
AU  - Yaribeygi H
AD  - Chronic Kidney Disease Research Center, Semnan University of Medical Sciences, 
      Semnan, Iran.
FAU - Maleki, Mina
AU  - Maleki M
AD  - Department of Physiology, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Sathyapalan, Thozhukat
AU  - Sathyapalan T
AD  - Department of Diabetes Endocrinology, Hull York Medical School, University of 
      Hull, UK of Great Britain and Northern Ireland, Hull, UK.
FAU - Jamialahmadi, Tannaz
AU  - Jamialahmadi T
AD  - Department of Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
AD  - Applied Biomedical Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Applied Biomedical Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, 
      Iran.
AD  - School of Medicine, The University of Western Australia, Perth, Australia.
AD  - Department of Medical Biotechnology, School of Pharmacy, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - HDC1R2M35U (empagliflozin)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Diabetic Nephropathies/drug therapy/etiology
MH  - Hypoglycemic Agents/therapeutic use/pharmacology
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/pharmacology
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - chronic kidney disease
OT  - diabetic nephropathy
OT  - empagliflozin
OT  - renoprotective effects
OT  - sodium-glucose cotransporter 2 inhibitor
EDAT- 2022/09/02 06:00
MHDA- 2023/05/19 06:42
CRDT- 2022/09/01 01:05
PHST- 2022/02/19 00:00 [received]
PHST- 2022/05/01 00:00 [revised]
PHST- 2022/05/16 00:00 [accepted]
PHST- 2023/05/19 06:42 [medline]
PHST- 2022/09/02 06:00 [pubmed]
PHST- 2022/09/01 01:05 [entrez]
AID - CMC-EPUB-126057 [pii]
AID - 10.2174/0929867329666220831151645 [doi]
PST - ppublish
SO  - Curr Med Chem. 2023;30(25):2850-2863. doi: 10.2174/0929867329666220831151645.